Praxis Precision Medicines, Inc. (PRAX)
NASDAQ: PRAX · Real-Time Price · USD
33.71
-3.40 (-9.16%)
Apr 3, 2025, 11:35 AM EDT - Market open
PRAX Employees
Praxis Precision Medicines had 116 employees as of December 31, 2024. The number of employees increased by 34 or 41.46% compared to the previous year.
Employees
116
Change (1Y)
34
Growth (1Y)
41.46%
Revenue / Employee
$73,733
Profits / Employee
-$1,576,026
Market Cap
679.70M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 116 | 34 | 41.46% |
| Dec 31, 2023 | 82 | -27 | -24.77% |
| Dec 31, 2022 | 109 | -30 | -21.58% |
| Dec 31, 2021 | 139 | 72 | 107.46% |
| Dec 31, 2020 | 67 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
PRAX News
- 4 weeks ago - Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 4 weeks ago - Praxis: A High-Risk, High-Reward Epilepsy Play Post Ulixacaltamide (Rating Upgrade) - Seeking Alpha
- 4 weeks ago - Praxis Precision Medicines Provides Update on Essential3 and Corporate Update - GlobeNewsWire
- 2 months ago - Praxis Precision Medicines to Present at Two February Investor Conferences - GlobeNewsWire
- 2 months ago - Praxis Precision Medicines Highlights 2025 Corporate Strategy and Business Priorities - GlobeNewsWire
- 3 months ago - Praxis Precision Medicines Announces Rare Pediatric Disease Designation Granted for Relutrigine in Dravet Syndrome - GlobeNewsWire
- 4 months ago - GeneDx to Expand Access to Exome Testing for Pediatric Epilepsy Patients with New Partners - Business Wire
- 4 months ago - Praxis Precision Medicines to Present at Upcoming December Investor Conferences - GlobeNewsWire